Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,397 across all filing types
Latest filing 2012-03-02 Investor Presentation
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Credit Suisse Global Health Care Conference, London
Investor Presentation Classification · 99% confidence The document text is titled "Credit Suisse - Global Health Care Conference" and contains detailed financial results, segment breakdowns (Fresenius Kabi, Helios, Vamed), financial outlooks for 2012, and historical performance data (2011 results). It is a presentation format, evidenced by section headers, bullet points summarizing achievements, and tables presenting financial figures. This structure strongly indicates an Investor Presentation (IP) given at a conference, rather than a formal regulatory filing like a 10-K or a brief Earnings Release (ER). The presence of a 'Safe Harbor Statement' and the context of a conference presentation solidify this classification.
2012-03-02 English
Release according to Article 26a, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is a 'Total Voting Rights Announcement' according to Article 26a of the WpHG (German Securities Trading Act). This type of announcement reports the total number of outstanding voting rights as of a specific date (February 29, 2012). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (Code: DVA), which covers official results from shareholder votes or related rights announcements.
2012-02-29 English
Citi Global Healthcare Conference, New York
Investor Presentation Classification · 99% confidence The document is titled "Citigroup - Global Health Care Conference" and is dated February 28, 2012. It contains extensive financial data, segment performance reviews (Fresenius Kabi, Helios, Vamed), financial outlooks for 2012, and discussions of long-term strategy and shareholder returns. This structure—a presentation given at an external industry conference, summarizing recent performance and future guidance—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or an Earnings Release (ER), but rather a detailed presentation package intended for investors and analysts.
2012-02-29 English
Fresenius SE & Co. KGaA: APP Pharmaceuticals receives FDA warning letter regarding Grand Island plant - no material financial impact expected
Legal Proceedings Report Classification · 99% confidence The document is an 'Ad-hoc' announcement dated February 24, 2012, disseminated according to § 15 WpHG. It details a specific event: APP Pharmaceuticals receiving a warning letter from the FDA regarding its Grand Island plant. This type of announcement concerns a significant, non-routine event that could impact the company's operations or financial standing, but it is not a standard periodic report (like 10-K or IR) or a formal shareholder communication (like DEF 14A). Since it reports on a legal/regulatory matter (FDA warning letter) that is material enough for an ad-hoc disclosure, it best fits the Legal Proceedings Report (LTR) category, as it directly relates to regulatory action/legal compliance issues. It is too specific for the general Regulatory Filings (RNS) fallback.
2012-02-24 English
Geschäftsjahr 2011 - Präsentation
Investor Presentation Classification · 98% confidence The document is titled "Analyst Meeting – 2011 Results" and is dated February 21, 2012. It contains detailed financial performance summaries for the year 2011 across various business segments (Fresenius Kabi, Fresenius Helios, Fresenius Vamed), including sales, EBIT, net income, growth rates, and outlooks. It also features slides typical of an investor presentation, such as CAGR charts, strategic trend analysis, and detailed P&L tables. This content structure strongly indicates a presentation prepared for investors or analysts, summarizing past performance and future strategy, which aligns perfectly with the definition of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER) or a transcript (CT).
2012-02-22 English
Fund Information / Factsheet 2012
Fund Information / Factsheet Classification · 98% confidence The document is titled "Factsheet FY / 2011" and contains a high-level summary of the company's profile, key financial figures for 2011 compared to previous years (Sales, EBIT, Net income, ROE, etc.), business segment descriptions, share information, and a financial calendar. This structure, presenting summarized historical performance and key data points in a concise format, strongly aligns with the definition of a Fund Information / Factsheet (FS). It is not a comprehensive Annual Report (10-K), an Interim Report (IR), or a standalone Audit Report (AR). It is also not a mere announcement of a report (RPA/RNS) as it contains substantial data.
2012-02-22 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.